{
    "nct_id": "NCT03130959",
    "official_title": "Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies",
    "inclusion_criteria": "* Must have received standard of care therapy, and there must be no potentially-curative treatment available, in one of the following cohorts:\n* A newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) that has been treated with radiation therapy (RT) but no chemotherapy\n* A histologically confirmed recurrent or progressive non-brainstem High Grade Glioma (HGG) previously treated with surgical resection and RT\n* A histologically confirmed medulloblastoma that has relapsed or is resistant to at least one line of prior therapy including surgery, RT, and chemotherapy\n* A histologically confirmed ependymoma that has relapsed or is resistant to at least one line of prior therapy including surgical resection and RT\n* A histologically-confirmed high grade CNS malignancy \"other than above\" which is recurrent or progressive after at least one line of prior therapy\n* Lansky play score (LPS) for â‰¤ 16 years of age or Karnofsky performance scale (KPS) for > 16 years of age assessed within two weeks of enrollment must be >= 60\n* A tumor sample must be available for submission to central laboratory (not required for DIPG)\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* An active, known, or suspected autoimmune disease\n* A concurrent condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of start of study treatment\n* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}